Presentation is loading. Please wait.

Presentation is loading. Please wait.

Pre-Tx 18 F-FDOPA PET Pre-Tx T1+C Post-Tx 18 F-FDOPA PET Difference Post-Pre Tx 18 F-FDOPA PET IOIS: 3401 Benjamin M. Ellingson, Ph.D., Dept. of Radiological.

Published bySolomon Gilmore Modified over 9 years ago

Similar presentations

Presentation on theme: "Pre-Tx 18 F-FDOPA PET Pre-Tx T1+C Post-Tx 18 F-FDOPA PET Difference Post-Pre Tx 18 F-FDOPA PET IOIS: 3401 Benjamin M. Ellingson, Ph.D., Dept. of Radiological."— Presentation transcript:

1 Pre-Tx 18 F-FDOPA PET Pre-Tx T1+C Post-Tx 18 F-FDOPA PET Difference Post-Pre Tx 18 F-FDOPA PET IOIS: 3401 Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM) RESPONDERChange in 18 F-FDOPA Signal + Increase - Decrease

2 Pre-Tx T1+C Difference Post-Pre Tx 18 F-FDOPA PET IOIS: 3401 Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM) Change in 18 F-FDOPA Signal + Increase - Decrease

3 Pre-Tx 18 F-FDOPA PET Pre-Tx T1+C Post-Tx 18 F-FDOPA PET Difference Post-Pre Tx 18 F-FDOPA PET IOIS: 2383 Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM) NON-RESPONDERChange in 18 F-FDOPA Signal + Increase - Decrease

4 Pre-Tx T1+C Difference Post-Pre Tx 18 F-FDOPA PET IOIS: 2383 Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM) NON-RESPONDERChange in 18 F-FDOPA Signal + Increase - Decrease

5 Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM) NON-RESPONDER Change in 18 F-FDOPA Signal + Increase - Decrease RESPONDER Pre-Tx DOPA Tumor Volume = 117.5 mL DOPA PRM % Decreasing DOPA Uptake = 93.0% % Increasing DOPA Uptake = 7.0 % Pre-Tx DOPA Tumor Volume = 18.3 mL DOPA PRM % Decreasing DOPA Uptake 72.8% % Increasing DOPA Uptake = 27.2 %

6 Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM) % Change in 18 F-FDOPA Signal + 100% - 100% RESPONDER > 50% Change % Decreasing DOPA Uptake = 93.0% % Decreasing > 25% change = 47.9% % Decreasing > 50% change = 18.2% % Increasing DOPA Uptake = 7.0 % % Increasing > 25% change = 0.9% % Increasing > 50% change = 0.0% > 25% Change All Changes

7 Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM) % Change in 18 F-FDOPA Signal + 100% - 100% NON-RESPONDER > 50% Change % Decreasing DOPA Uptake = 72.8% % Decreasing > 25% change = 31.9% % Decreasing > 50% change = 2.7% % Increasing DOPA Uptake = 27.2 % % Increasing > 25% change = 3.2% % Increasing > 50% change = 0.05% > 25% Change All Changes

8 Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM) % Decreasing DOPA% Increasing DOPA

9 Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 POSITRON EMISSION TOMOGRAPHY PARAMETRIC RESPONSE MAP (PET-PRM) NON-RESPONDER Change in 18 F-FDOPA Signal + Increase - Decrease RESPONDER VOLUME OF DECREASING DOPA UPTAKE = 7.4 mL VOLUME OF INCREASING DOPA UPTAKE = 1.2 mL VOLUME OF DECREASING DOPA UPTAKE = 175.5 mL VOLUME OF INCREASING DOPA UPTAKE = 0.8 mL

10 XXXX 18 F-FDOPA PET Parametric Response Maps (PET PRMs) Change in PET Signal -5000+ 5000 Baseline: 3/10/09 Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 10/20/09 3/30/10 10/12/10 2/15/11

11 XXXX 18 F-FDOPA PET Parametric Response Maps (PET PRMs) Baseline: 3/10/09 Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011

12 Pre-Tx 18 F-FDOPA PET Pre-Tx T1+C Pre-Tx 18 F-FLT PET Combined 18 F-FLT and 18 F-FDOPA FLTDOPAFLT+DOPA IOIS: 3401 Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 MALIGNANT MARKER MAPS ( 18 F-FLT and 18 F-FDOPA )

13 Benjamin M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, 2011 MALIGNANT MARKER MAPS ( 18 F-FDOPA + CBV + ADC )

Download ppt "Pre-Tx 18 F-FDOPA PET Pre-Tx T1+C Post-Tx 18 F-FDOPA PET Difference Post-Pre Tx 18 F-FDOPA PET IOIS: 3401 Benjamin M. Ellingson, Ph.D., Dept. of Radiological."

Similar presentations

Herceptin as a Phase 0 Imaging Example. Phase 0 Trials in Oncology Drug Development Steven M. Larson, M.D. Nuclear Medicine Svc, Department of Radiology.

Herceptin as a Phase 0 Imaging Example. Phase 0 Trials in Oncology Drug Development Steven M. Larson, M.D. Nuclear Medicine Svc, Department of Radiology.
Functional Diffusion Maps (fDMs) for Brain Tumor Treatment Response Monitoring Benjamin M. Ellingson, Ph.D. Assistant Professor of Radiology Dept. of Radiological.

Functional Diffusion Maps (fDMs) for Brain Tumor Treatment Response Monitoring Benjamin M. Ellingson, Ph.D. Assistant Professor of Radiology Dept. of Radiological.
Diffusion Physics H 2 O in the body is always in random motion due to thermal agitation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen.

Diffusion Physics H 2 O in the body is always in random motion due to thermal agitation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen.
Diffusion MRI is sensitive to brain tumor cell density Clinical ADC and cell density are negatively correlated (Sugahara, 1999; Lyng, 2000; Chenevert,

Diffusion MRI is sensitive to brain tumor cell density Clinical ADC and cell density are negatively correlated (Sugahara, 1999; Lyng, 2000; Chenevert,
DegenerationRegeneration Traumatic Injury Degenerative Disease Radiation/Chemotherapy Brain Tumors Stem Cells & Regenerative Medicine B.M. Ellingson, Ph.D.,

DegenerationRegeneration Traumatic Injury Degenerative Disease Radiation/Chemotherapy Brain Tumors Stem Cells & Regenerative Medicine B.M. Ellingson, Ph.D.,
Response Evaluation of Gastrointestinal Stromal Tumors (GIST)

Response Evaluation of Gastrointestinal Stromal Tumors (GIST)
Author Name 2, Author Name 5 1 Dept. of Neurology, 2 Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA To demonstrate.

Author Name 2, Author Name 5 1 Dept. of Neurology, 2 Dept. of Radiological Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA To demonstrate.
Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,

Disclosures Paid Consultant, MedQIA LLC Paid Consultant, Agios Pharmaceuticals, Inc. Consultant, Genentech Consultant, Siemens Medical Systems B.M. Ellingson,
Diffusion Physics H 2 O in the body is always in random motion due to thermal agitation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen.

Diffusion Physics H 2 O in the body is always in random motion due to thermal agitation B.M. Ellingson, Ph.D., Dept. of Radiological Sciences, David Geffen.
1. 3.27 M 2. 79.5 M 3. 0.135 M 4. 7.43 M 5. Not Listed 1234567891011121314151617181920 21222324252627282930.

M M M M 5. Not Listed

Positron Emission Tomography (PET) scans allow for functional imaging of the body’s metabolism, making it an effective tool for locating cancerous tumors.

Positron Emission Tomography (PET) scans allow for functional imaging of the body’s metabolism, making it an effective tool for locating cancerous tumors.
Molecular Imaging “101” The Role of Molecular Imaging in Cancer Briefing and Roundtable Washington, DC July 22, 2008 Martin G. Pomper, MD, PhD Russell.

Molecular Imaging “101” The Role of Molecular Imaging in Cancer Briefing and Roundtable Washington, DC July 22, 2008 Martin G. Pomper, MD, PhD Russell.
Fig. 1. 18FDG PET-CT in patient with cutaneous T-cell lymphoma with treatment response. Baseline (A) and post treatment (B) axial fused PET-CT images demonstrate.

Fig FDG PET-CT in patient with cutaneous T-cell lymphoma with treatment response. Baseline (A) and post treatment (B) axial fused PET-CT images demonstrate.
Fig. 2. Arterial fluorodeoxyglucose (FDG) uptake related to atherosclerosis. On positron emission tomography (PET) coronal (A), PET/CT fusion coronal (B),

Fig. 2. Arterial fluorodeoxyglucose (FDG) uptake related to atherosclerosis. On positron emission tomography (PET) coronal (A), PET/CT fusion coronal (B),
Fig F-fluoride positron emission tomography (PET) in atherosclerosis

Fig F-fluoride positron emission tomography (PET) in atherosclerosis
Correlation of 18F-FDG Avid Volumes on Pre–Radiation Therapy and Post–Radiation Therapy FDG PET Scans in Recurrent Lung Cancer  Nadya Shusharina, PhD,

Correlation of 18F-FDG Avid Volumes on Pre–Radiation Therapy and Post–Radiation Therapy FDG PET Scans in Recurrent Lung Cancer  Nadya Shusharina, PhD,
Applications of Radioactivity

Applications of Radioactivity
Applications for Preclinical PET/MRI

Applications for Preclinical PET/MRI
Impact of moving target on measurement accuracy in 3D and 4D PET imaging—a phantom study  Yunfeng Cui, PhD, James Bowsher, PhD, Jing Cai, PhD, Fang-Fang.

Impact of moving target on measurement accuracy in 3D and 4D PET imaging—a phantom study  Yunfeng Cui, PhD, James Bowsher, PhD, Jing Cai, PhD, Fang-Fang.

Similar presentations

Ads by Google